Ruti Aga's Six-Year Ban: The Fake Prescription Weighed More Than the Substance
**Câu trả lời cốt lõi:** Ruti Aga, 32 tuổi, chân marathon Ethiopia, bị Athletics Integrity Unit cấm thi đấu sáu năm tính từ ngày 10 tháng 9, sau khi mẫu thử dương tính với methylprednisolone và cô bị xác định làm giả đơn thuốc do một người họ hàng không có đăng ký hành nghề y ký. **Dữ kiện chính:** - Án gồm hai năm cho chất cấm và bốn năm cho hành vi làm giả hồ sơ, thi hành nối tiếp theo Bộ luật WADA. - Methylprednisolone là glucocorticoid tổng hợp thuộc nhóm S9, chất được chỉ định, chỉ bị cấm trong thi đấu. - Phòng khám trên đơn thuốc không tồn tại; nơi công tác cũ của người ký xác nhận người này chưa từng làm việc ở đó. - Aga vô địch Tokyo Marathon 2019 và ba lần về nhì tại các World Marathon Majors. - Án kết thúc ở tuổi 38, xóa toàn bộ phí xuất hiện và suất mời dự giải. **Nguồn:** Thông báo của Athletics Integrity Unit (AIU) thuộc World Athletics; mốc hiệu lực án cấm ngày 10 tháng 9. **Hỏi đáp liên quan:** Hỏi: Vì sao án lên tới sáu năm? Đáp: Hai năm cho chất cấm cộng bốn năm cho hành vi gian lận hồ sơ, thi hành nối tiếp chứ không song song. Hỏi: Aga có thể kháng cáo không? Đáp: Cô có thể đưa vụ việc lên CAS, nhưng ba nguồn xác minh độc lập khiến khả năng đảo ngược rất thấp. Hỏi: Vụ việc ảnh hưởng thế nào tới đường chạy nữ Ethiopia? Đáp: Chiều sâu đội hình Ethiopia hấp thụ gần như hoàn toàn suất bị rút, thiệt hại chủ yếu nằm ở uy tín thương mại của thương hiệu chạy đường dài.
The clinic named on the prescription replied that it had never issued that prescription. The employer the signatory claimed to have worked for confirmed she had never been on the payroll. And the signatory herself — a relative of the athlete — held no medical registration number. Three answers, added together, that weighed more than the substance.

Ruti Aga, 32, the Ethiopian marathoner who won the 2026 Tokyo Marathon and finished runner-up at World Marathon Majors three times, has been banned for six years. The notice came from the Athletics Integrity Unit (AIU), World Athletics' independent integrity body, and set the start of the sanction at 10 September. The document does not state the year. I keep that gap rather than filling it with inference, because in a doping file a date missing its year is a marker to be flagged, not a number to be rounded.
The six years are assembled from two parts. Two years for the presence of methylprednisolone in a sample. Four years for tampering with evidence during results management. The two parts do not run side by side. They stack.
The case begins at a race almost nobody in Vietnam noticed: a half marathon in China in March, which Aga won. The AIU notice does not disclose the mark. No time, no course data, nothing to set against a personal best or a qualifying standard. For a writer, that is an awkward void — but a meaningful one, because it tells you the triggering race was not a championship event but a commercial road race.
Aga attributed the positive test to treatment for a knee injury. That is the only claim from the athlete's side, and it is unverified in the source. It is also the hinge of the entire case: if the glucocorticoid use was genuinely therapeutic, then what decided the sanction was not the substance but how she and the people around her handled the aftermath.
One correction matters, and I make it because it changes how the whole file reads. Several reports describe methylprednisolone as an anabolic steroid. It is not. It is a synthetic glucocorticoid — a corticosteroid — sitting in WADA class S9, prohibited in competition only, and classified as a Specified Substance. Those three features carry concrete legal consequences: a softer baseline than an anabolic steroid, a higher plausibility of a therapeutic explanation, and a therapeutic use exemption (TUE) that genuinely exists if the paperwork is done properly.
Put another way, the easy half of this case should have been the substance.
I have followed women's road running for five years, and what these files teach is that the anti-doping system does not run on public emotion. It runs on the architecture of the violation. The WADA Code is explicit that where an athlete commits multiple anti-doping rule violations, the periods of ineligibility are served consecutively, not concurrently. That is why two plus four becomes six rather than four.
The most telling feature of the Ruti Aga case is not the six years but their architecture: the penalty for the cover-up is twice the penalty for the substance. The system is pricing a forged document above contaminated blood.
Look at the evidentiary chain the AIU assembled. The prescription carried the name of a clinic that does not exist. The signatory was a relative with no medical registration. She claimed to have used an old prescription pad from a former workplace. That workplace was asked and confirmed she had never worked there. The clinic was asked and confirmed the prescription was not theirs.
Every link in that chain could be broken by a single verification call. And the AIU made the calls. This is standard verification practice: direct confirmation from the medical facility, registration checks, payroll checks. The era in which a signed and stamped piece of paper could survive an investigation ended long ago. What struck me was the amateurism of the whole construction — no real clinic, no real doctor, no real pad, no real employer. Someone who understood the process would not have built something that collapses so easily.
And that amateurism is itself a diagnosis. It suggests nobody around Aga had the expertise to tell her that if this really was knee-injury treatment, a legal route existed. Apply for a TUE. Declare the route and timing honestly. File a retroactive exemption where an emergency leaves no time to file in advance. A genuine treatment record, honestly declared, could have produced no violation at all, or a far lighter sanction without the aggravating tampering count.
I have been hearing stories of athletes managing everything alone since my first years in the locker room. In 2026, at 24, commentating on a Phong Phu Ha Nam women's football match, a senior male colleague told me that women writing about football only needed to describe emotions, and that tactics were for men. I did not argue. I went home and rewatched the team's last ten matches, drawing their high-press charts by hand. I heard those lines in the locker room. Now I retell them in data.
My method has not changed since. In 2026, when the pandemic shut the pitches, I opened Excel and rewatched 214 matches from the women's U-20 World Cups between 2026 and 2026, logging every shift in the full-back role. An entire tournament lived in twenty thousand rows. The same habit applies to athletics: when a case is published, I read the structure of the sanction before the conclusion, because the structure tells you what the investigators believed mattered.

In this case, the structure speaks plainly.
The second part of the story is the arithmetic of age. Aga was 32 when the sanction was announced. In women's marathoning, the peak window commonly extends to around 35 and beyond, supported by aerobic base and pacing experience. At 32 she was inside the peak, not past it. A six-year ban running from 10 September returns her to eligibility at roughly 38.
Some women's marathoners still race well at 38. The distance between racing well and racing at World Marathon Majors podium level is enormous, and six years without competition is not a pause — it is a rupture in coaching, medical support, invitations, in everything that makes an elite athlete. The probability of returning at the old level is very low.
Functionally, this is a career-ending sanction, not a suspended one.
The third part is economics. The March half marathon in China will almost certainly have its result annulled, taking the prize money with it. For a world-class marathoner, income does not come from championship prizes — it comes from appearance fees, from World Marathon Majors invitations, from shoe and sponsor contracts. Six years of ineligibility erases all three at once. There is no mechanism for maintaining an appearance fee for an athlete who is not permitted to appear.
I have written before that the Chinese road-racing circuit is a demand market, not a competitive one. These races pay for fast East African names on their courses. That money has pulled hundreds of Ethiopian and Kenyan athletes into Asian road events, many of them small-scale, with thin medical oversight and effectively no compliance support. Aga was one node in that network. Her case is a reminder that the network has nobody handling paperwork for the athletes inside it.
That leads to a question about the national system. Ethiopia's women's marathon depth is among the thickest in the world. A slot removed from that start line is refilled almost instantly; nobody at national performance level has to worry. On the roads, Aga is a replaceable node. For her, it is an entire career.
One thing cannot be replaced so quickly: the commercial credibility of the Ethiopian distance-running brand. It is a shared asset of athletes, managers and race organisers. A case featuring a forged prescription signed by a family member erodes that asset in a way a simple positive test does not.
This is where I want to push back on the popular reading.
The popular reading divides the world into clean athletes and cheats. It is tidy, shareable, and misses the most important part. This file contains two violations of very different natures. The first is the presence of a prohibited substance — a Specified Substance, prohibited in competition, with a plausible therapeutic route for a knee injury and an exemption mechanism that already exists. The second is the invention of a clinic that does not exist.
Those are not the same kind of act. Yet the system processes them on the same scale, and that scale prices the second at twice the first. That is a deliberate choice, not an accident. Anti-doping bodies want the message to be that covering up is more dangerous than the original error, because successful cover-ups destroy the system's ability to separate treatment from cheating.
I agree with that logic. But I want to name the blind spot it creates.
This system punishes the amateur more heavily than the professional. An athlete with a real doctor, a real clinic, a real lawyer and a TUE filed on time can walk away from the same positive sample with a far lighter sanction — or none at all. An athlete with nothing but an old prescription pad gets six years.
That is not an argument for reducing Aga's sanction. It is an observation about structure: sanction length in doping cases reflects not only the severity of the violation but the quality of the support team behind the athlete. And support quality scales with money. An East African marathoner racing Asian road events might earn a few thousand dollars in appearance fees per start, but there is no compliance line item in that income structure.
There is a second unfairness in the coverage. Calling the substance an anabolic steroid leads the public to picture a large-scale physical cheating operation. The reality is a corticosteroid prohibited in competition, a Specified Substance, used for a knee injury. The gap between those two images is wide, and it inflates reputational damage well beyond the severity of the substance offence. What will persist in public memory is not the corticosteroid but the non-existent clinic and the relative's signature. That is a far more viral story than Aga's actual standing in the marathon world — she is elite, but not a household name.
On responsibility, I do not read this as a sign of organised cheating inside the Ethiopian system. The evidence points the other way: one relative, one old pad, one invented clinic, and three verification calls sufficient to dismantle the whole thing. Organised cheating does not operate like that. This is an individual, amateur case, detected quickly.

Responsibility does not stop with Aga, though. Whoever advised her, drafted the file, or managed her — if any of them helped construct the prescription, they are within the AIU's reach. Tampering cases routinely extend to the entourage, and this one fits the pattern.
On appeal, Lausanne is the only remaining lever. But a record containing three independent verification answers from three separate sources — an employer denying employment and a clinic denying the prescription among them — is not the kind of record that reverses easily. I would not bet on it.
What interests me more is what remains unanswered. The source does not state the route of administration. If this was an intra-articular injection close to competition, the in-competition prohibition was triggered exactly as designed, and the absence of a TUE becomes the first error. There is also a possibility the AIU reviews Aga's stored samples, standard practice once tampering is established. Those samples do not automatically become a problem, but they sit within reach.
I am not retelling this case to darken a sanction. I am retelling it because it exposes a gap that women's road running is paying for: the gap between an increasingly sophisticated anti-doping system and an athlete base with increasingly thin legal and medical support. An injection for a knee should have been one line in a medical file. It became six years, because nobody built her a legal road through that moment.
Women's athletics does not need approval through pity, and it does not need protecting by lowering standards. It needs to be read through the file. And the file here says something very specific: the cost of having nobody sitting beside an athlete to tell her where she is going wrong is higher than every appearance fee she ever collected.
If there is a change worth watching after this case, it is federations and athlete managers being held accountable for the medical paperwork of the people they guide. An athlete cannot build a legal firewall around herself out of nothing. When the system is fast enough to phone a clinic within days, preparing a TUE properly should be just as fast.
Aga will not race at that level again. But the next generation of East African runners is still queuing at Asian road races, still running for appearance fees, and still without anyone sitting beside them holding a correct file.
